

PRODUCT INFORMATION

| | |
|------------------------------|---|
| Common Name | MG-A271, MGA271 |
| Conjugate | Unconjugated |
| Synonyms | B7-H3;CD276;B7 homolog 3 |
| Applications | ELISA; Flow Cyt |
| Recommended Dilutions | ELISA 1:5000-10000; Flow Cyt 1:100 |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | Humanized |
| IgG type | Human IgG1 – kappa |
| Reactivity | Human |
| Target | B7-H3 |
| Uniprot ID | Q5ZPR3 |
| Description | Anti-B7-H3 (enoblituzumab biosimilar) mAb |
| Delivery | In Stock |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |



Anti-B7-H3 (enoblituzumab biosimilar) mAb ELISA
0.2 µg of Human B7H3, mFc-His Tagged protein per well




Figure 1. ELISA plate pre-coated by 2 µg/ml (100 µl/well) Human B7-H3, mFc-His tagged protein PME100012 can bind Anti-B7-H3 Neutralizing antibody in a linear range of 0.24-31.25 ng/ml.




Figure 2. Flow cytometry analysis with 1µg/mL Anti-B7-H3 (enoblituzumab biosimilar) mAb (BME100010) on Hela cells (Blue histogram) or isotype control mAb on Hela cells (Red histogram).




**A**

Figure 3. Flow cytometry analysis of antigen binding of anti-human B7-H3 mAb(BME100010). (A) A clear peak shift of BME100010 was seen compared to the control when incubated with B7-H3-expressing Hela cells, indicating strong binding of BME100010 to B7-H3. Antibodies were incubated at 2 μ g/mL.

